Deferasirox
Therapeutic Category
- Chelating Agent
Innovator Brand
GMP
DMF
Filed
Under Filing
Sample
Indication
Exjade (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. In these patients, exjade has been shown to reduce liver iron concentration and serum ferritin levels.
CTX Lifesciences, is one of the leading Active Pharmaceutical Ingredients ( API ) manufacturer and supplier globally for Deferasirox with CAS#201530-41-8. We are a leading exporter of Deferasirox with CAS#201530-41-8. We are a trusted supplier with API exports in more than 87 Countries including the US, Europe, Brazil, Latin America, China, Korea,Iran, Middle East and other emerging markets.
CTX Lifesciences is one of the leading API manufacturer & supplier of Deferasirox with CAS#201530-41-8. This product is provided from our GMP compliant plant with product made under complete cGMP conditions. We provided with documentation support Drug Master File(DMF). Our manufacturing plant at Surat has accreditation by US-FDA, EDQM , EMA , ANVISA, KFDA, MOH-IRAN, Health Canada & Russian Authorities.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.